The next generation of biopharma companies is remarkably well equipped scientifically. Platform technologies, richer data and more flexible manufacturing partners have shortened the path from discovery to the clinic. What hasn’t kept pace, for many of these companies, is the operating model behind the science.

Teams that were well served by spreadsheets and an entry-level accounting package during discovery suddenly need to manage clinical supply, contract manufacturers, multiple currencies and investor reporting — often all at once. The result is a familiar set of growing pains.

The signs a company has outgrown its systems

Most leadership teams recognize the symptoms long before they name the cause:

  • The monthly close takes longer every quarter and depends on a handful of people who know where the numbers live
  • Clinical supply and inventory are tracked in separate files that rarely agree
  • Contract manufacturers and research organizations send data in different formats, each reconciled by hand
  • Audit preparation consumes weeks of senior time
  • Every new study, partner or country adds another spreadsheet

None of these problems is fatal on its own. Together they slow decisions, raise compliance risk and pull scientists and finance leaders into administrative work.

Why the timing matters

There’s a common belief that enterprise systems can wait until commercialization. In practice, the months before a pivotal trial or launch are the worst possible time to replace core systems. Teams are stretched, regulators are watching and there’s no room for a disruptive cutover.

Companies that put a scalable foundation in place earlier — while volumes are still modest — tend to launch more smoothly. Processes are established, data is clean and the system has been through at least one audit cycle before the stakes rise.

What a scalable foundation includes

A foundation for growth doesn’t need to be large. It needs to be the right shape. For emerging biopharma, that typically means:

  1. Integrated finance with multi-entity and multi-currency support, cost tracking by program and study, and a close process that can be repeated with confidence.
  2. Clinical and commercial supply with batch management, expiry tracking and visibility into inventory held by partners.
  3. Partner collaboration through standard integrations with contract manufacturers, logistics providers and research organizations.
  4. Validation-ready processes documented and tested in a way that supports GxP requirements from the start.

A private cloud edition of SAP Cloud ERP gives companies this foundation along with the control regulated environments often require, while keeping the path open to future innovation.

Avoiding the common traps

Even with the right platform, some early choices make growth harder than it needs to be:

  • Over-customizing early. Rebuilding today’s workarounds in a new system locks in yesterday’s processes.
  • Treating validation as a final step. Building compliance into design and testing is faster than retrofitting it.
  • Underestimating data. Product, batch and partner data need owners and standards long before go-live.
  • Choosing a partner without industry depth. Life sciences processes have nuances that generic templates miss.

Questions to ask before your next milestone

Leadership teams can gauge their readiness with a few simple questions:

  • Could we close the books in a week if our auditors asked tomorrow?
  • Do we know, today, how much clinical supply our partners hold and when it expires?
  • Would adding a new country or partner mean a new spreadsheet — or a configuration change?
  • Are our core processes documented well enough to stand up to an inspection?

If the honest answer to more than one of these is no, it’s time to start planning — ideally a year or more before the next major milestone.

A foundation that grows with the pipeline

The most successful emerging companies treat their core systems the way they treat their pipeline: as an asset that must be ready before it’s needed. They start with a focused scope, build on standard processes and add capability as programs advance.

For a closer look at the specific hurdles in this sector, see our research on six ERP obstacles facing emerging biopharma, or read how one company moved to a unified ERP in record time.

Planning for your next stage of growth? Contact us to talk with our life sciences team.